ANN ARBOR, Mich., March 13, 2018 /PRNewswire/ -- Strata Oncology, a precision oncology company, today announced that
"We are excited to join a collaborative group of leading cancer centers across the country working to ensure broad, timely patient access to precision medicine," said Robert J. Amato, DO, Acting Director of the Division of Oncology at UTHealth McGovern Medical School and the Chief of the Division of Oncology at Memorial Hermann Cancer Center-TMC.
Members leverage the StrataNGSTM test, an 87-gene assay that sequences both DNA and RNA, as the foundation of comprehensive, integrated solution to deliver precision oncology system-wide. StrataNGS is available to all advanced solid tumor and lymphoma patients at no cost through the Strata Trial, a nationwide observational study providing tumor profiling and trial matching for 100,000 patients with advanced cancer.
"We welcome Aurora Health Care and UTHealth as partners committed to advancing precision oncology," said Dan Rhodes, Ph.D., CEO of Strata Oncology. "The Network continues to expand with both academic and community healthcare systems collaborating to lead the way in advancing precision medicine for cancer patients."
"This partnership reinforces our commitment to transform healthcare and deliver superior clinical outcomes," said Michael Thompson, MD, PhD, hematologist/oncologist for Aurora Cancer Care and Medical Co-Director, Oncology Precision Medicine Program at Aurora Health Care. "By partnering with Strata Oncology, Aurora Health Care will be one of a select group of health systems in the country offering advanced cancer patients increased access to precision medicine. Eligible cancer patients at Aurora Health Care will have access to tumor molecular profiling, with an opportunity to enroll on cancer clinical trials that will be available at Aurora."
The Network's additional members include:
About Strata Oncology Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials. The Strata Trial provides no-cost tumor sequencing to patients with advanced cancer, while offering pharmaceutical companies exclusive access to stratified patient populations to shorten clinical development timelines. Strata aims to accelerate the approval of new medicines for cancer patients by bringing together a collaborative network of key stakeholders including patients, providers and pharmaceutical companies. For more information visit www.strataoncology.com.
Media Inquiries: Strata Oncology Media Relations firstname.lastname@example.org 734-527-1000
View original content:http://www.prnewswire.com/news-releases/strata-oncology-announces-new-partnerships-with-aurora-health-care-and-uthealth-300612718.html
SOURCE Strata Oncology
Subscribe to our Free Newsletters!